Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion for ...

Global pharmaceutical leader, Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today ...

The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), for use in cancer patients at risk of infection due to chemotherapy. Filkri is indicated for patients receiving ...

Lupin expects to maintain US sales at around $1 billion over the next two years, supported by a steady stream of new product launches. The company has several launches lined up across injectables, ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed by Cinfa ...

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution ...

A Japan-based biopharma company with two operating pillars: a biosimilars business (development and supply of approved ...

Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III ...

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter results.

Aurobindo Pharma Limited on February 27, 2026 announced the completion of a United States inspection at its subsidiary's facility, stating that the US Food and Drug ...